MOLECULAR PHARMACOLOGY

EDITOR: RAYMOND J. DINGLEDINE, Emory University

ASSOCIATE EDITORS: P. JEFFREY CONN, Emory University
MICHAEL M. GOTTESMAN, National Institutes of Health
KENNETH P. MINNEMAN, Emory University
EDWARD T. MORGAN, Emory University
RICHARD R. NEUBIG, University of Michigan

MANAGING EDITOR: ESMERALDA GALÁN

EDITORIAL ASSISTANT: ELLEN M. CIOSEK

EDITORIAL AND ADVISORY BOARD

NIGEL J. M. BIRDSALL, National Institute for Medical Research, Mill Hill, United Kingdom
RANDY D. BLAKELY, Vanderbilt University
JOEL BOCKAERT, Centre National de la Recherche Scientifique, France
EDWARD BRESNICK, University of Massachusetts Medical Center
JOAN HELLER BROWN, University of California, San Diego
MARC G. CARON, Duke University
CHARLES CHAVKIN, University of Washington
JOHN W. DALY, National Institutes of Health
STEVEN K. FISHER, University of Michigan
ALFRED G. GILMAN, University of Texas Southwestern Medical Center, Dallas
ROBERT I. GLAZER, Georgetown University
FRANK J. GONZALEZ, National Cancer Institute
F. PETER GUENGERICH, Vanderbilt University
JAMES R. HALPERT, University of Arizona
HEIDI HAMM, University of Illinois College of Medicine
R. ADRON HARRIS, University of Colorado Health Sciences Center, Denver
STEPHEN B. HOWELL, University of California, San Diego
PAUL A. INSEL, University of California, San Diego
KARL H. JAKOBS, University of Essen, Germany
ERIC F. JOHNSON, The Scripps Research Institute
BRIAN K. KOBILKA, Stanford University
DENNIS R. KOOP, Oregon Health Sciences University
ROBERT J. LEFKOWITZ, Duke University
LEE E. LIMBIRD, Vanderbilt University
THOMAS M. LINCOLN, University of Alabama at Birmingham
JOEL LINDEN, University of Virginia
ROBERT L. MACDONALD, University of Michigan Medical Center

RONALD P. MASON, National Institute of Environmental Health Sciences
MARK L. MAYER, National Institutes of Health
JAMES O. MCNAMARA, Duke University
RICHARD J. MILLER, University of Chicago
GRAEME MILLIGAN, University of Glasgow, Scotland
T. J. MURPHY, Emory University
CHARLES E. MYERS, Jr., University of Virginia Health Sciences Center
S. R. NAHORSKI, University of Leicester, United Kingdom
DAVID L. NELSON, Lilly Research Laboratories
ERIC J. NESTLER, Yale University
KIM A. NEVE, Veterans Affairs Medical Center, Portland
ALLAN B. OKEY, University of Toronto, Canada
PAUL ORTIZ DE MONTELLANO, University of California, San Francisco
GERRY S. OXFORD, University of North Carolina at Chapel Hill
ERIC M. PARKER, Schering-Plough Research Institute
ALAN POLAND, University of Wisconsin
MICHAEL A. ROGAWSKI, National Institutes of Health
DARRYLE D. SCHOEPP, Eli Lilly and Company
GARY L. STILES, Duke University
CATHERINE D. STRADER, Merck Research Laboratories
PALMER TAYLOR, University of California, San Diego
TODD A. VERDOORN, Vanderbilt University
MICHAEL J. WARING, University of Cambridge, England
DAVID J. WAXMAN, Boston University
GARY L. WESTBROOK, Vollum Institute
MICHAEL M. WHITE, Medical College of Pennsylvania
STEVEN A. WRIGHTON, Lilly Research Laboratories

BOARD OF PUBLICATIONS TRUSTEES

KENNETH E. MOORE, Chairman
KAY A. CROKER, Executive Officer

William O. Berndt
D. Craig Brater
David B. Bylund

William A. Catterall
Marlene L. Cohen
Raymond J. Dingledine

John A. Harvey
Raymond F. Novak
Marcus M. Reidenberg

About the cover: Depiction of a model of the cholecystokinin B receptor, showing longitudinal views of the seven transmembrane helices (blue), the intracellular domains 11 (yellow), 12 (red), and 3 (green), and the carboxyl-terminal tail (deep yellow). Mutational deletion of the carboxyl group from the Asp1106 residue in the TMII region (yellow) substantially weakened the ability of this receptor to couple to its G protein. From Jagerschmidt A., N. Guillaume, N. Goudreau, B. Maigret, and B.-P. Roques. Mutation of Asp1106 in the second transmembrane domain of the cholecystokinin B receptor increases antagonist binding and reduces signal transduction. Mol. Pharmacol. 48:783–789 (1995).